title: Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice.
abstract: Targeted disruption of the receptor for glycoprotein hormone, FSH (FSH-R) causes a gene dose-related endocrine and gametogenic abnormality in female mice. The resulting FSH-R knockout (FORKO) mutants have disordered estrous cycles, ovulatory defects, and atrophic uterus. The heterozygous animals that initially show reduced fertility undergo early reproductive senescence and stop breeding altogether. Lack of FSH-R signaling in females causes severe ovarian underdevelopment producing chronic estrogen deficiency. This was accompanied by increases in serum testosterone levels. Ovarian aromatase gene transcription and translation are unaltered in the mutants. Early loss of estrogen in the null mutants leads to obesity and skeletal abnormalities that intensify with age producing (kyphosis), a hunchback appearance. Both these changes also become apparent in older heterozygous mice coincident with early reproductive senescence. The expression of nuclear estrogen receptor(s) alpha and beta genes and the corresponding proteins in the ovary and uterus of FORKO mice appear to be intact. The loss of ovarian estrogen creates an imbalance in A and B forms of the progesterone receptor in the uterus of both heterozygotes and null mutants. Some of the changes we have documented here in FORKO mice are reminiscent of the ovarian dysfunction and other major symptoms that are usually associated with estrogen deficiency. In null mutants, estradiol-17beta administration promptly induced uterine growth and reversed the accumulation of adipose tissue indicating that estrogen receptors are functional. Thus, the phenotypes evident in these genetically altered FSH-R mutants may provide an experimental system to explore the effects of estrogenic compounds on different targets including the ovary in a nonsurgical setting.
authors.affiliation: Molecular Reproduction Research Laboratory, Clinical Research Institute of Montréal, Québec, Canada.
authors.forename: N
authors.initials: N
authors.lastname: Danilovich
authors.forename: P S
authors.initials: PS
authors.lastname: Babu
authors.forename: W
authors.initials: W
authors.lastname: Xing
authors.forename: M
authors.initials: M
authors.lastname: Gerdes
authors.forename: H
authors.initials: H
authors.lastname: Krishnamurthy
authors.forename: M R
authors.initials: MR
authors.lastname: Sairam
mesh_terms: D000818:Animals; D001284:Atrophy; D001847:Bone Diseases / Q000235:genetics*; D003433:Crosses, Genetic; D004958:Estradiol / Q000032:analysis / Q000097:blood / Q000494:pharmacology; D004967:Estrogens / Q000172:deficiency* / Q000502:physiology; D005260:Female; D006579:Heterozygote; D007738:Kyphosis / Q000235:genetics; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009765:Obesity / Q000235:genetics*; D009929:Organ Size / Q000187:drug effects; D011374:Progesterone / Q000032:analysis / Q000097:blood; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology; D011962:Receptors, FSH / Q000172:deficiency* / Q000235:genetics; D012098:Reproduction; D013739:Testosterone / Q000097:blood; D014599:Uterus / Q000473:pathology; D014621:Vagina / Q000473:pathology
chemical_list: D004967:Estrogens; D018160:Receptors, Cytoplasmic and Nuclear; D011962:Receptors, FSH; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol